首頁 > 市場調查報告書 > 醫療設備

透析設備

市場調查報告書

商品編碼

1373401

全球腹膜透析設備市場-2023-2030

Global Peritoneal Dialysis Equipment Market -2023-2030

出版日期: 2023年10月18日 | 出版商:

DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

末期腎病 (ESRD) 或嚴重腎衰竭可透過腹膜透析 (PD) 技術進行治療。當腎臟不再有效運作時，腹膜透析是一種腎臟替代療法，有助於清除體內的廢物和多餘液體。患者的偏好、生活方式和醫療要求決定應使用手動 CAPD 或自動 APD。 CAPD 每天需要多次更換透析液，而 APD 則使用機器進行夜間更換。

技術進步提高了腹膜透析裝置的有效性、安全性和可用性。由於這些技術的發展，越來越多的患者選擇腹膜透析作為一種治療形式。由於人口老化更容易患腎臟相關疾病，因此對透析治療（特別是腹膜透析）的需求增加。

動力學

腹膜透析的優勢越來越明顯

根據 2023 年發表在《生理學前沿》上的文章，對於腎衰竭或末期腎病患者來說，血液透析 (HD) 並不總是合適的治療選擇。腹膜透析的採用已有 40 多年的歷史，但由於多種原因，全球範圍內的情況差異很大。根據全球腎臟健康地圖集，平均每百萬人 (pmp) 中有 38.1 人接受慢性 PD 治療，明顯低於全球 HD 盛行率估計的 298.4 人 (pmp)。

腹膜透析有許多好處，包括更好的血壓管理、更好的腎功能維護以及更靈活和自主的治療計劃，給予病人更多的自主權。一些患者和醫療服務提供者可能會發現 PD 是一種理想的替代方案，因為它可以降低患者和醫療保健系統的成本。

慢性腎臟病盛行率不斷上升

全球有超過 8 億人（佔總人口的 10% 以上）患有慢性腎臟病，這是一種退化性疾病。患有糖尿病、高血壓、老年人、女性和有色人種的人更有可能患有慢性腎臟病。由於低收入和中等收入國家最沒有準備好應對其影響，因此它們承受著慢性腎臟病帶來的異常沉重的負擔。

根據疾病管制與預防中心的數據，大約 3550 萬美國成年人（即 14%）被認為患有 CKD。† 高達 90% 的 CKD 患者不知道自己的病情。三分之一患有嚴重慢性腎臟病的成年人不知道自己的病情。患有 CKD 的人更有可能年齡在 65 歲以上 (34%)，而不是 45 歲至 64 歲之間 (12%) 或 18 歲至 44 歲之間 (6%)。女性 (14%) 患有 CKD 的比例略高於男性 (12%)。與非西班牙裔亞裔 (14%) 和非西班牙裔白人 (12%) 成年人相比，非西班牙裔黑人成年人 (20%) 的 CKD 盛行率更高。

慢性腎臟病患者人數眾多，影響嚴重，應加強防治力道。導致市場對腹膜透析設備的需求不斷增加。

對腹膜透析的認知有限

患者和醫療保健提供者缺乏對腹膜透析（PD）作為末期腎臟病（ESRD）治療選擇的了解，這是一個嚴重的問題，可能會產生多種影響。 ESRD 患者可能不知道 PD 是治療選擇。由於缺乏知識，患者可能會延遲開始透析治療，或可能完全決定不進行透析治療。結果，人們可能會錯過適當控制疾病的機會。

如果患者不知道帕金森氏症，他們可能會認為自己幾乎沒有治療腎衰竭的選擇。正因為如此，更多的患者可能會選擇中心血液透析，而如果他們知道 PD 的優點，他們本來可以選擇這種療法。

感染風險

腹膜透析 (PD) 期間必須將導管插入腹部，這會增加感染的風險。在初次腹膜透析導管置入手術中切開腹壁切口，然後將導管引入腹膜腔。與任何手術一樣，這種技術有可能傳播細菌。

患者的腹膜透析治療可能持續數月甚至數年，在此期間導管留在原處。導管放置的時間越長，細菌侵入腹膜腔的可能性就越大。

End-stage Renal Disease (ESRD) or severe kidney failure is treated with peritoneal dialysis (PD) technology. When the kidneys are no longer working effectively, peritoneal dialysis is a type of renal replacement therapy that aids in removing waste and extra fluid from the body. The patient's preferences, way of life, and medical requirements determine whether manual CAPD or automatic APD should be used. Several times a day, CAPD requires human exchanges of dialysis fluid, whereas APD employs a machine for nocturnal exchanges.

The effectiveness, safety, and usability of peritoneal dialysis apparatus have been enhanced by technological advances. As a result of these technical developments, more patients are opting for peritoneal dialysis as a form of treatment. The need for dialysis treatments, particularly peritoneal dialysis, has increased due to an aging population's greater susceptibility to kidney-related disorders.

Dynamics

Increasing Advantages of Peritoneal Dialysis

As per the article published in Frontiers in Physiology in 2023, hemodialysis (HD) is not always an appropriate therapy option for those with kidney failure or end-stage kidney disease. The adoption of peritoneal dialysis, which has been around for more than 40 years, has varied greatly globally for several reasons. According to the Global Kidney Health Atlas, 38.1 per million individuals (pmp) on average undergo chronic PD treatment, which is significantly less than the 298.4 pmp estimated global prevalence of HD.

Peritoneal dialysis has a number of benefits, including better blood pressure management, better renal function maintenance, and a more flexible and autonomous treatment plan that gives patients more autonomy. Some patients and providers may find PD to be a desirable alternative because it can have lower expenses for both patients and the healthcare system.

The Rising Prevalence of Chronic Kidney Disease

More than 800 million people worldwide-more than 10% of the overall population-have chronic kidney disease, which is a degenerative disorder. Persons with diabetes mellitus, hypertension, elderly persons, women, and people of color are more likely to develop chronic kidney disease. Because they are least prepared to handle its effects, low- and middle-income countries bear a disproportionately heavy burden from chronic kidney disease.

According to the Centers for Disease Control and Prevention, approximately 35.5 million US adults, or 14%, are believed to have CKD.† Up to 90% of persons with CKD are unaware of their condition. One in three adults with severe CKD is unaware of their condition. People with CKD are more likely to be over 65 (34%) than between 45 and 64 (12%) or between 18 and 44 (6%). Women (14%) have CKD at a somewhat higher rate than males (12%). Compared to non-Hispanic Asian (14%) and non-Hispanic White (12%) adults, non-Hispanic Black adults (20%) had a higher prevalence of CKD.

Increased efforts for better prevention and treatment should be made as a result of the large number of afflicted people and the serious negative effects of chronic renal disease. Results in increasing demand for peritoneal dialysis equipment in the market.

Limited Awareness of Peritoneal Dialysis

The lack of knowledge of peritoneal dialysis (PD) as a treatment option for end-stage renal disease (ESRD) among patients and healthcare providers is a serious problem that can have numerous effects. It is possible that patients with ESRD are unaware that PD is a therapy option. Due to a lack of knowledge, patients may postpone starting their dialysis treatment or perhaps decide against it altogether. As a result, people might pass up the chance to properly control their disease.

Patients may believe they have few options for treating their renal failure if they are unaware of PD. Because of this, more patients may choose in-center hemodialysis when they could have opted for PD had they known about its advantages.

Infection Risks

Catheter must be inserted into the abdomen during peritoneal dialysis (PD), and doing so increases the risk of infection. An abdominal wall incision is made during the initial PD catheter placement surgery, and the catheter is then introduced into the peritoneal cavity. Like with any operation, there is a chance that this technique will spread bacteria.

The patient's peritoneal dialysis therapy may last months or even years, during which time the catheter is left in place. Bacterial invasion into the peritoneal cavity is more likely the longer the catheter is in place.

Segment Analysis

The global peritoneal dialysis equipment market is segmented based on product, treatment type, end-users and region.

The Automated Peritoneal Dialysis (APD) segment accounted for approximately 45.6% of the market share

APD is a form of PD that involves employing a dialysis machine to deliver and drain the dialysate automatically and with a minimum of human involvement. APD exchanges can be completed overnight while you sleep and normally take between 8 and 12 hours. One of the kidney functions that dialysis treatment substitutes is ultrafiltration, which is the evacuation of fluid from the patient's body. Ultrafiltration is used in peritoneal dialysis (PD) to remove fluid via the peritoneal membrane.

In some cases, APD may have a stronger ultrafiltration effect, allowing for more fluid to be evacuated during each exchange and lowering edema brought on by an excess of fluid. Patients would only need to attach and disconnect their catheter from the APD machine once per day because APD exchange is typically performed overnight. Patients would then need to connect and disconnect their catheter from the dialysate bags numerous times during the day, which can dramatically increase their risk of infection. CAPD exchanges are typically performed three to four times throughout the day.

Geographical Penetration

North America segment accounted for approximately 45.7% of the market share

North America has been a dominant force in the global peritoneal dialysis equipment market. It has long proven difficult to administer kidney dialysis to little, vulnerable neonates because the majority of dialysis devices are made for adults. However, the Children's Hospital of Los Angeles is now able to offer this life-saving treatment to infants thanks to a unique system designed especially for them.

The technology, known as the Carpediem Cardio-Renal young Dialysis Machine, is recognized by the Food and Drug Administration and offers young patients as small as 2.5 kilos (about 5 pounds) with continuous renal replacement therapy.

For instance, in November 2022, the nation's top manufacturer of dialysis equipment, Fresenius Medical Care North America (FMCNA), announced that its Liberty Select Cycler has received FDA 510(k) approval, enabling remote therapy management using the Kinexus Therapy Management Platform. The goal of this improvement is to improve the home therapy experience for PD patients and medical professionals.

Clinicians for home dialysis are helped by Liberty Select and Kinexus to make crucial decisions based on timely, reliable treatment data summaries. To help evaluate the efficacy of the program, Care Teams will also have access to up to 90 days' worth of treatment data history. The dialysis clinician can modify the therapy plan as necessary to provide quick, data-driven interventions. Market-available Liberty Select cyclers can be upgraded to support remote therap management.

COVID-19 Impact Analysis:

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global peritoneal dialysis equipment market. Since patients getting in-center hemodialysis frequently have comorbid conditions that place them at an increased risk for serious illness, COVID-19 raised questions about the safety of these individuals. As a result, peritoneal dialysis and other home-based dialysis techniques gained popularity. To lessen virus exposure, a lot of patients and medical professionals looked for methods that let patients practice dialysis at home.

Due to worries about COVID-19, some patients may have put off starting peritoneal dialysis or switching to it. The adoption of peritoneal dialysis was dependent on how carefully healthcare professionals and patients weighed the risks and advantages of various treatment alternatives.

Key Developments

In June 2023, AWAK Technologies (AWAK) and Singapore General Hospital (SGH) stated the beginning of a pre-pivotal clinical trial with the enrollment of their first patient to examine the safety and effectiveness of an upgraded Automated Wearable Artificial Kidney Peritoneal Dialysis (AWAK PD) device.

Competitive Landscape

The major global players in the market include AWAK Technologies, Baxter International Inc., Medtronic plc, Fresenius Medical Care North America, Terumo Corporation, Utah Medical Products, Inc., Polymedicure, Angiplast, Merit Medical Systems, and Newsol Technologies Inc.

Why Purchase the Report?

To visualize the global peritoneal dialysis equipment market segmentation based on product, treatment type, end-users and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of peritoneal dialysis equipment market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global peritoneal dialysis equipment market report would provide approximately 61 tables, 54 figures and 186 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product
3.2. Snippet by Treatment Type
3.3. Snippet by End-user
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Advantages of Peritoneal Dialysis
  - 4.1.1.2. The Rising Prevalence of Chronic Kidney Disease
- 4.1.2. Restraints
  - 4.1.2.1. Limited Awareness of Peritoneal Dialysis
  - 4.1.2.2. Infection Risks
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Product

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 7.1.2. Market Attractiveness Index, By Product
7.2. Systems And Consumables*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.2.3. Peritoneal Dialysis Solution
- 7.2.4. Peritoneal Dialysis Transfer Sets
- 7.2.5. Peritoneal Dialysis Catheters
- 7.2.6. Others

8. By Treatment Type

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 8.1.2. Market Attractiveness Index, By Treatment Type
8.2. Continuous Ambulatory Peritoneal Dialysis (CAPD)*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Automated Peritoneal Dialysis (APD)

9. By End-user

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Dialysis Centres
9.4. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. UK
  - 10.3.6.3. France
  - 10.3.6.4. Italy
  - 10.3.6.5. Spain
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan
  - 10.5.6.4. Australia
  - 10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. AWAK Technologies*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Baxter International Inc.
12.3. Medtronic plc
12.4. Fresenius Medical Care North America
12.5. Terumo Corporation
12.6. Utah Medical Products, Inc
12.7. Polymedicure
12.8. Angiplast
12.9. Merit Medical Systems
12.10. Newsol Technologies Inc

LIST NOT EXHAUSTIVE